310 related articles for article (PubMed ID: 32106568)
21. Functionalized TiO
Cędrowska E; Pruszynski M; Majkowska-Pilip A; Męczyńska-Wielgosz S; Bruchertseifer F; Morgenstern A; Bilewicz A
J Nanopart Res; 2018; 20(3):83. PubMed ID: 29576738
[TBL] [Abstract][Full Text] [Related]
22. Magnetite nanoparticle-loaded anti-HER2 immunoliposomes for combination of antibody therapy with hyperthermia.
Ito A; Kuga Y; Honda H; Kikkawa H; Horiuchi A; Watanabe Y; Kobayashi T
Cancer Lett; 2004 Aug; 212(2):167-75. PubMed ID: 15279897
[TBL] [Abstract][Full Text] [Related]
23. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Tamura K; Tsurutani J; Takahashi S; Iwata H; Krop IE; Redfern C; Sagara Y; Doi T; Park H; Murthy RK; Redman RA; Jikoh T; Lee C; Sugihara M; Shahidi J; Yver A; Modi S
Lancet Oncol; 2019 Jun; 20(6):816-826. PubMed ID: 31047803
[TBL] [Abstract][Full Text] [Related]
24. Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts.
Costantini DL; McLarty K; Lee H; Done SJ; Vallis KA; Reilly RM
J Nucl Med; 2010 Jul; 51(7):1084-91. PubMed ID: 20554744
[TBL] [Abstract][Full Text] [Related]
25. Evaluating the potential of 188Re-SOCTA-trastuzumab as a new radioimmunoagent for breast cancer treatment.
Luo TY; Tang IC; Wu YL; Hsu KL; Liu SW; Kung HC; Lai PS; Lin WJ
Nucl Med Biol; 2009 Jan; 36(1):81-8. PubMed ID: 19181272
[TBL] [Abstract][Full Text] [Related]
26. Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/neu receptors using MRI.
Chen TJ; Cheng TH; Chen CY; Hsu SC; Cheng TL; Liu GC; Wang YM
J Biol Inorg Chem; 2009 Feb; 14(2):253-60. PubMed ID: 18975017
[TBL] [Abstract][Full Text] [Related]
27. Lanthanide-Doped SPIONs Bioconjugation with Trastuzumab for Potential Multimodal Anticancer Activity and Magnetic Hyperthermia.
Gawęda W; Osial M; Żuk M; Pękała M; Bilewicz A; Krysinski P
Nanomaterials (Basel); 2020 Feb; 10(2):. PubMed ID: 32046284
[TBL] [Abstract][Full Text] [Related]
28. Carbon-Coated Iron Oxide Nanoparticles Promote Reductive Stress-Mediated Cytotoxic Autophagy in Drug-Induced Senescent Breast Cancer Cells.
Lewińska A; Radoń A; Gil K; Błoniarz D; Ciuraszkiewicz A; Kubacki J; Kądziołka-Gaweł M; Łukowiec D; Gębara P; Krogul-Sobczak A; Piotrowski P; Fijałkowska O; Wybraniec S; Szmatoła T; Kolano-Burian A; Wnuk M
ACS Appl Mater Interfaces; 2024 Mar; 16(12):15457-15478. PubMed ID: 38483821
[TBL] [Abstract][Full Text] [Related]
29. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial.
Emens LA; Esteva FJ; Beresford M; Saura C; De Laurentiis M; Kim SB; Im SA; Wang Y; Salgado R; Mani A; Shah J; Lambertini C; Liu H; de Haas SL; Patre M; Loi S
Lancet Oncol; 2020 Oct; 21(10):1283-1295. PubMed ID: 33002436
[TBL] [Abstract][Full Text] [Related]
30. Enhanced therapeutic action of Trastuzumab loaded Zn
Singh S; Akhil Varri VS; Parekh K; Misra SK
Colloids Surf B Biointerfaces; 2023 Dec; 232():113579. PubMed ID: 37864913
[TBL] [Abstract][Full Text] [Related]
31. Complex of TNF-α and Modified Fe
Teo P; Wang X; Chen B; Zhang H; Yang X; Huang Y; Tang J
Cancer Biother Radiopharm; 2017 Dec; 32(10):379-386. PubMed ID: 29265918
[TBL] [Abstract][Full Text] [Related]
32. Superior antitumor activity of a novel bispecific antibody cotargeting human epidermal growth factor receptor 2 and type I insulin-like growth factor receptor.
Chen C; Zhang Y; Zhang Y; Li J; Tsao SW; Zhang MY
Mol Cancer Ther; 2014 Jan; 13(1):90-100. PubMed ID: 24227890
[TBL] [Abstract][Full Text] [Related]
33. Cytotoxicity of breast cancer cells overexpressing HER2/neu by 213Bi-Herceptin radioimmunoconjugate.
Zhang DY; Li Y; Rizvi SM; Qu C; Kearsley J; Allen BJ
Cancer Lett; 2005 Feb; 218(2):181-90. PubMed ID: 15670895
[TBL] [Abstract][Full Text] [Related]
34. Anti-HER2 antibody and ScFvEGFR-conjugated antifouling magnetic iron oxide nanoparticles for targeting and magnetic resonance imaging of breast cancer.
Chen H; Wang L; Yu Q; Qian W; Tiwari D; Yi H; Wang AY; Huang J; Yang L; Mao H
Int J Nanomedicine; 2013; 8():3781-94. PubMed ID: 24124366
[TBL] [Abstract][Full Text] [Related]
35. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of HER2 inhibitors in combination with or without pertuzumab for HER2-positive breast cancer: a systematic review and meta-analysis.
Chen S; Liang Y; Feng Z; Wang M
BMC Cancer; 2019 Oct; 19(1):973. PubMed ID: 31638935
[TBL] [Abstract][Full Text] [Related]
37. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
38. Targeted antitumor efficacy and imaging via multifunctional nano-carrier conjugated with anti-HER2 trastuzumab.
Choi WI; Lee JH; Kim JY; Heo SU; Jeong YY; Kim YH; Tae G
Nanomedicine; 2015 Feb; 11(2):359-68. PubMed ID: 25262581
[TBL] [Abstract][Full Text] [Related]
39. Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab.
Boskovitz A; McLendon RE; Okamura T; Sampson JH; Bigner DD; Zalutsky MR
Nucl Med Biol; 2009 Aug; 36(6):659-69. PubMed ID: 19647172
[TBL] [Abstract][Full Text] [Related]
40. Fe
Yin Q; Gao X; Zhang H; Zhang Z; Yu X; He J; Shi G; Hao L
Biomed Mater; 2024 Apr; 19(3):. PubMed ID: 38626777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
